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Background: The tissue biobanking of specific biological residual materials, which constitutes a useful resource for
medical/scientific research, has raised some ethical issues, such as the need to define which kind of consent is
applicable for biological residual materials biobanks.
Discussion: Biobank research cannot be conducted without considering arguments for obtaining the donors’
consent: in this paper we discuss to what extent consent in biobank research on oncological residual materials has
to be required, and what type of consent would be appropriate in this context, considering the ethical principles of
donation, solidarity, protection of the donors’ rights and the requirements of scientific progress. Regarding the
relationship between informed consent and tissue collection, storage and research, we have focused on two
possible choices related to the treatment of data and samples in the biobank: irreversible and reversible
anonymization of the samples, distinguishing between biobank research on residual materials for which obtaining
consent is necessary and justified, and biobank research for which it is not. The procedures involve different
approaches and possible solutions that we will seek to define. The consent for clinical research reported in the
Helsinki Declaration regards research involving human beings and for this reason it is subordinate to specific and
detailed information on the research projects.
Summary: An important ethical aspect in regard to the role of Biobanks is encouraging sample donation. For
donors, seeing human samples being kept rather than discarded, and seeing them become useful for research
highlights the importance of the human body and improves the attitude towards donation. This process might also
facilitate the giving of informed consent more willingly, and with greater trust.
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The tissue biobanking of biological residual materials
constitutes a good resource for bio-medical research and
has raised some ethical issues, such as the need to un-
derstand the beliefs and values of the donor patients [1],
including the motivations underlying consent or refusal
to give the samples to biobanks [2], and the balance
between the protection of individual and society’s com-
mon good.* Correspondence: luciana.caenazzo@unipd.it
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reproduction in any medium, provided the orBiological residual materials are obtained from patho-
logical waste from surgical activities (surgical removal
and biopsies of neoplasias); they are collected for ana-
lysis and are usually stored in formalin in Pathology
Departments.
The conservation of paraffin blocks for decades cer-
tainly represents an enormous resource as a biobank,
even though its utility is somewhat limited for molecular
analyses, considering that many studies have demon-
strated that prolonged fixation in formaldehyde entails
cross-linking reactions and above all DNA denaturation,
with consequent partial or total failure of the polymerase
chain reaction (PCR) amplification process, compromis-
ing the quality of amplified DNA [3-7].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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diagnostic purposes, it can be stored with the purpose of
future genetic studies: in this case samples should be
frozen immediately after collection in order to maintain
a good quality of DNA/RNA or, more generally, of mac-
romolecules. Various investigations have examined the
integrity of macromolecules within periods of time after
the excision of the tissue sample. The non-conclusive
nature of the published studies, and the impossibility of
precisely defining the susceptibility of various genes and
their expression to hypoxic damage, highlight that the
collection of tissues destined for storage in biobanks
should take place as quickly as possible [8-12].
For these reasons, the choice of sampling neoplasias
that are destined for research is guided by the diagnostic
needs of the tissue sample and the timing and mode of
sample conservation, from excision to transport to the
Pathology laboratory, storage in the laboratory and the
disposal of the tissues.
During the operation it is necessary to send the repre-
sentative part of the neoplasia to the pathologist for ana-
lysis. The representative fragment of the tumor has to be
sent to the pathologist for diagnosis, but the surgeon
may also keep other fragments of tissue not appropriate
for diagnostic procedure, so the surgeon can decide im-
mediately to keep part of the tissue and store it. The
pathologist fixes the tissue in formalin and encloses in
paraffin a fragment that is representative of the tumor.
From the paraffin blocks he/she obtains the histological
slides to analyze under the microscope and makes the
diagnosis. Once the amount of tissue necessary for
immediate or future diagnosis has been preserved, the
pathologist can store the residual materials in formalin
solution, or store them in small pieces at −80°C.
Biobanks of frozen oncological residual materials are
undoubtedly expensive; however, it could be useful and
important to consider their possible involvement in par-
ticular oncological studies, such as linking abnormalities
in the tissue to disease aetiology, and analyzing gene ex-
pression and gene regulation to identify the mechanisms
of tumorigenesis and to study epigenetic phenomena [13].
For these reasons, a reorganization of the “tissue conser-
vation” in Pathology Departments would also be useful for
fresh samples, and would require new organizational strat-
egies, from the presence of a pathologist in the operating
theatre to sampling techniques. Moreover, the evermore
frequent need to determine molecular alterations on tis-
sues collected years ago makes standardization of all tissue
management procedures fundamental, starting with fix-
ation (the process of fixation constitutes the first and es-
sential step for the tissue conservation for pathological
purposes).
Moving on from these technical explanations to
how residual materials can be obtained, regarding therelationship between informed consent and tissue col-
lection, and storage and research, in this paper we
highlight two possible choices related to the treat-
ment of data and samples in the biobank: irreversible
and reversible anonymization of the samples. The pro-
cedures involve different approaches and possible po-
licy making strategies that we will seek to define,
considering that donation of residual biological ma-
terial, collected for diagnosis, could be beneficial for
society from the perspective of the common good, ra-
ther than being directly affecting the individual’s health
status.Discussion
Informed consent in oncological residual material
biobanks
In general, the ethical discussion on biobank research in-
volves a number of questions concerning the relation-
ship between the individual, society and biobanks.
In general, researchers obtained and used tissue sam-
ples for defined purposes which were disclosed to con-
tributors. In these cases the consent form regarded the
specific research project. Today, in the case of biobanks,
the donor of the sample may not be affected by the re-
search, and future uses of the samples may be unknown
at the moment of the consent. However, biobank re-
search cannot be conducted without considering argu-
ments for obtaining the donors’ consent [14,15].
While the consent proposed by the Helsinki Decla-
ration [16] is specific for clinical trials, which involve
humans beings and are clearly oriented towards pharma-
cological or other interventional studies, which have to
be described exactly, in biobank research the consent for
residual material involves research whose future pecu-
liarity and aims cannot be clearly identified at moment
of consent.
As suggested by Gefenas et al. [17] it seems important
to discuss justifiable divergences from the paradigm pro-
posed by the Helsinki Declaration about consent. It
seems appropriate “to tune different levels of regulatory
stringency (including regulations on acceptable types of
consent) to different types of biological materials ac-
cording to the interests of the donors involved”.
The question is to what extent consent in biobank re-
search on oncological residual materials has to be re-
quired and what type of consent would be appropriate
in this context [17-19], considering the influence coming
from the ethical aspects of donation, solidarity and the
respect of donor’s autonomy through the informed con-
sent, considering, as the most important aspect, how to
find a balance between the individual’s rights and the
interest/benefit of society from the perspective of the
common good.
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to different form of applicable consent [17,20-23] in the
field of biobanking.
We may consider and justify the action of leaving the
residual neoplastic sample in the biobank as a “dona-
tion” that constitutes an advantage for medical research
in general. Such a donation could be considered benefi-
cial for society in the perspective of the common good
in biobanking, an aspect that we will further discuss.
In particular, in the case of oncology many factors may
play a central role in the decision-making process of
donation. In fact, depending on the type of cancer and
the stage of the disease, different physical and mental
symptoms can be noted as pain, anxiety, and depression
related to the risk of serious side-effects or death; fur-
thermore the genetic information related to cancer may
have effects on the family as a whole community and on
its single members.
In biobank research, the distinction between the
anonymization and pseudonymization of samples and
data, as a matter of personal data protection, has ob-
tained a great attention from an ethical point of view
[24]. When data and samples are anonymized, according
to the European understanding, the link between the
original donor and the data or material is deleted. When
they are pseudonymized, the donor can always be re-
identified by the biobank operators using a code. Re-
searchers who work with the biobank samples do not
receive the full identity of the original sample but just
its code. It is sometimes argued that in the strict sense
of the word (i.e., absolute anonymity) can never be
achieved, because theoretically, genetic samples and data
can be re-attributed to the donor. Art 3 of Appendix to
the Recommendation Rec (2006)4 of the Committee of
Ministers of Europe to member states on research on
biological materials of human origin [25] states that ano-
nymity is already achieved when a person cannot be
identified “with reasonable efforts”. This can be inter-
preted as a “pragmatic” definition of anonymity which
should not be confused with absolute anonymity.
Regarding the relationship between informed consent
and tissue collection, storage and research, we have fo-
cused on two possible choices related to the treatment
of data and samples in the biobank: irreversible and re-
versible anonymization (the latter meaning the previous
cited pseudonymization) of the samples, meaning, on the
basis of what is established in the Recommendation we
have cited, that “Identifiable biological materials are
those biological materials which, alone or in combin-
ation with associated data, allow the identification of
the persons concerned either directly or through the use
of a code” as a reversible anonymization and, “Non-
identifiable biological materials, hereafter referred to as
“unlinked anonymized materials”, are those biologicalmaterials which, alone or in combination with associ-
ated data, do not allow, with reasonable efforts, the
identification of the persons concerned” as irreversible
anonymization.
We refer in this context to the term “reversible ano-
nymization” instead of pseudonymization to highlight
the contrast with the completely different process of
“irreversible anonymization”.
This procedure is applicable only to the samples to
be collected in the future and not to those already in
storage.
Consent options could be performed following an
OPT-OUT model which consists in informing the pa-
tient before the surgical operation about the possibility
to donate completely anonymous tissue samples ob-
tained from residual oncological materials, which would
otherwise be discarded after the operation. Alternatively,
the OPT-IN model is represented by a classic request
for consent before the operation; this can be assimilated
to a broad and precautionary consent, meaning that in
the consent form provided for research use of residual
material the specifics of the future research projects are
unknown [17].
The procedures involve different approaches and pos-
sible solutions that we will seek to define.
Irreversible anonymization of the sample
The main question regards which kind of informed con-
sent is necessary for a procedure of irreversible anony-
mization of samples and data.
If the tissue sample will be irreversibly anonymized
and no information regarding the donor can ever be
obtained from it, the donor is guaranteed in his/her pri-
vacy but does not have any return of results because it
will be impossible to link the data to the donor’s sample.
In this case, we think it would be best to consider
a “presumed consent”, rather than an actual consent
request.
In case of the OPT-OUT model a special hospital staff
would be in charge of the information process by direct
(or individual) information or by other general strategies,
for example in the information for the consent to the
surgery procedure.
In other words, the practical form of the OPT-OUT
consent can be simply explained as follows: “I collect
your residual material sample with a standardized pro-
cedure, then I inform you that it will be stored and
preserved and you may refuse. If you say “no” to its
preservation, this is a refusal and I will discard the
sample; otherwise, if you don’t reply I consider you in
agreement, allowing the preservation and use of the
anonymized sample”.
Irreversible anonymization should be considered an
exceptional procedure because with this kind of samples
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history, lifestyle, personal and health information. How-
ever, in our opinion, this may be useful when the alter-
native is the loss of the sample, when the donor would
have refused to give his residual material with an OPT-
IN form, and when it could be useful to collect samples
for basic research in which the above mentioned infor-
mation on the donor is not necessary.
In this particular situation it should be a duty to reno-
vate the informed consent process for an OPT-OUT
choice.
Irreversibly anonymized samples can constitute a re-
source for basic research where information about the
donor is not necessary for permitting the saving of sam-
ples linked to individual information for disease-oriented
research. However, this option should not be not offered
simultaneously as alternative to the OPT-IN form, but
just as a second choice, because the general goal of a
biobank is to obtain samples related to disease history,
lifestyle, personal and health information, so the OPT-
IN model is overriding.
Reversible anonimyzation of the sample
In this case, we think that information and consent
should be clear and in a “OPT-IN” form, because the do-
nor’s sample is identified by a code that constitutes the
link with the donor’s data.
The decision to donate residual tissues for biobanking
may take little from the donor in terms of time com-
mitment or harm above and beyond the donation of
oncological residual materials from tissues collected for
diagnostic or therapeutic purposes. On the other hand,
the potential benefits to society are relatively unclear,
given the open-ended nature of residual material bank-
ing research, which may make less clear to the donors
the reasons why they should participate.
Therefore, we should think of a broad consent with
the following suggestions on the information:
– for how long the samples will be stored;
– who has access to donor’s information (name,
surname, qualification, degree, etc.) and who is the
person responsible for the link when, for the
reversible process, a code is attributed to the
sample;
– what the sample will be used for: it is important to
indicate the specific branch of research, in the view
of obtaining consent from the beginning for
conducting, at a later time, analyses without the
necessity of requesting further consent, (for example
a broad consent may be requested for research into
the genetics of colon cancer or regarding tumor
etiopathology of the colon);
– the value of the donation for medical research.In general we have to consider that often, in these sit-
uations, patients must discover what residual material
biobanking is, why it is beneficial and how they may
contribute when they meet the doctor before a surgical
operation. Decisions to donate tissues are therefore likely
to be strongly influenced by the information that clinicians
and researchers provide about the risks and benefits of
biobanking [18].
The consent processes for residual material banking
should take account of the range of potential motives
that may influence a patient’s decision to donate tissues
[26]. Such a process might involve asking the patients
what they know about this kind of biobank, what they
expect from donating their residual tissues for research,
whether they have any anxieties about donating their re-
sidual materials, and if so, what they are and how they
came to their decision to donate. Tissue donation ap-
pears to be viewed as part of a generalized or indirect
form of reciprocity in which the good will of others
is reciprocated by the donor’s contribution and by
which the act of donation contributes to society’s com-
mon good.
In particular, in case of oncological research the de-
cision of donating may be influenced on one hand by
an attitude of altruism that influences in a positive
way the patient’s decision process in favor of dona-
tion; on the other hand, feelings of fear, anger or re-
fusal related to the conditions of the illness may lead
the patient to deny any kind of contribution to the
common good. Furthermore, genetic information con-
cerning cancer may provide information about a rela-
tive and may cause concerns for family members who
are already involved in managing the disruptive ef-
fects of a cancer diagnosis.
The decision-making process and the information
process will take time, but ultimately it is likely to in-
crease the validity and importance of the consent pro-
cess and increase engagement with biomedical research
and trust in its importance.
We can assume that in both donations, made with an
OPT-OUT consent for irreversible and OPT-IN for re-
versible sample anonymization, the assessment whether
to keep the biological residual materials as a donation
would be made in a perspective of solidarity, and cancer
patients should be helped in perceiving it as a possibility
to contribute to the common good, instead of refusing
any social exchange with other people.
The difference in the form of consent is justified, in
our opinion, by the fact that irreversible anonymization
implies a lower risk (in general terms) for the donor, and
with the purpose of usefulness of a biobank for the
whole society rather than for the single patient, a pre-
sumed silent assent seems to be enough and to facilitate
the process of donation.
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OUT is justified by a research objective and there is no
violation of individual rights because there is no risk of
the violation of privacy, and the autonomy of the donor
is respected.
In contrast, the reversible anonymization of the sam-
ple could represent a greater risk for the donors, regard-
ing, for example, the violation of privacy, as well as the
harm from group stigmatization [27,28], cultural or reli-
gious objection to particular forms of research [26], the
return of results, and the donation should be explicitly
intended and therefore should derive from an explicit
consent. An explicit consent is necessary, since in this
situation the OPT-OUT consent is an overly weak
expression for consent for donors. Biobank research pro-
duces risks different from other types of medical re-
search, for example pharmacological or interventional
clinical trials, because the risk of bodily harm is very
small or even non-existent. The risks regarding biobank
research could be: the knowledge/communication of a
specific disease entity (for example, in case of mental/in-
fectious diseases), the stigmatization of individuals, or
the misuse of scientific health data for other purposes.
Furthermore, incidental findings cannot be excluded.
Regarding the context of donation we can cite the
work by Morrell et al. in New South Wales (Australia)
based on a series of qualitative interviews with patients
who had donated tissue to a tumor bank [29]. The study
shows that “participants in this study overwhelmingly
expressed their willingness to donate leftover tumor tis-
sue for research because of “the good” that it might
bring to others. . . these “others” included family, friends,
disease community members (present and future), future
generations and at times simply “anyone”.
In general, in the case of tissue donation to a biobank
in which donors spontaneously expressed concern that
their donations should benefit others, they did not per-
ceive that they would be assuming a cost through the
act of donation.
The donation of tissue residual materials to a biobank
is made, altruistically, with the purpose to improve the
scientific research and promote people’s health. People
donating tissue residual material know that this kind of
donation will be of no direct benefit for their health sta-
tus or in medical terms. Researchers have no contact
with donors and the donors may be easily changed and
chosen randomly in the population. The duty to contrib-
ute to medical research considered here is not free from
restrictions for researchers, especially in case of cancer
patients, who are in need of special care and multidi-
mensional support. These restrictions are provided, un-
der appropriate circumstances, by ethical committees
and by the law with the aim to guarantee trustworthi-
ness and confidence in research.Another important ethical aspect regarding biobanks
on oncological residual material is to promote an educa-
tional social plan encouraging sample donation.
As remarked by Hoedemaekers et al. “For the ade-
quate development of basic rights and shared values
something else is essential: participatory self-rule. Every
individual should be able to engage in public debate, and
actively take part in social and community life to foster
and promote the important values and liberties. This
means that social participation is also seen as a core
value” [30,31].
Regarding biobanking this duty doesn’t seem to be
hard, if we consider that for donors, seeing human
samples being kept rather than discarded, and seeing
them becoming useful for research, since donation
might benefit others and contribute to a generalized
system of solidarity, the importance of the human bo-
dy is highlighted and the attitude towards donation is
improved.
This process might also facilitate the giving of in-
formed consent more trustfully and willingly, granting,
in this context, that donation permission is nothing
more than an automatic response.
Concerning this aspect, in Morrell’s study it is re-
ported that donors had a high level of willingness to
donate tumor tissue for research. Donation was often
considered to be “not a big deal” given that it involved
the use of tissues which would be discarded anyway and
was perceived as involving little or no credible risk [29].
Despite the sense that tumor donation was “a lot of
fuss about nothing,” donors expressed considerable sa-
tisfaction at the thought that their donation might be-
nefit others and contribute to a generalized system of
reciprocity.
The expression of OPT-OUT consent will be a con-
dition for the irreversible anonymization of data and
samples, this form of “consent” doesn’t involve risks for
donors and constitutes an advantage for society’s com-
mon good; and the silent assent consent seems to be
sufficient to facilitate the process of a direct donation.
In contrast, the reversible for example anonymization
of the sample could represent a greater vulnerability for
the donors, regarding the violation of privacy and the re-
turn of results and the donation should be explicitly
intended and therefore should derive from an explicit
consent.
The structure and content of the informed consent for
biobank should be different from the one reported by
the Helsinki Declaration regarding clinical trials, which
doesn’t seem to fit adequately to the purposes of bioban-
king, considering the necessity of adjusting the existing
notions of informed consent and government regula-
tion to the new realities of donors’ samples donation
to biobanks [32].
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Helsinki Declaration regards research involving human
beings and for this reason it is subordinate to specific
and detailed information on the research projects. The
OPT-IN consent for oncological residual material bio-
banks, which involves research on reversible anonymized
samples, should be viewed as a “broad” consent, well-
structured in terms of information, where the approval
of future research projects, different from the original
ones, has to be the responsibility of the Ethical Commit-
tee. In this way we can guarantee the balance between
the protection of individual rights and the interest/bene-
fit of society in creating and maintaining biobanks.
Biobank research, aiming to improve medical and scien-
tific knowledge obviously related to prevention, treat-
ment and therapy of diseases that is clearly in the
interest of the single donor, is considered as belonging
to the society as a whole. This will mean that when pa-
tients are faced with decisions of whether or not to par-
ticipate in residual materials biobanking, they will be
better equipped with a motivational understanding of its
significance, which is necessary to reflect upon and in-
terpret the situation and what is being asked of them,
and to realize their active solidarity for society’s com-
mon good.Summary
Biological residual materials can be obtained from surgi-
cal activities or from pathological waste material col-
lected for analysis and stored in formalin. This material
can be stored in Biobanks with the purpose of future re-
search. Regarding the relationship between informed
consent and tissue collection, storage and research, two
choices are possible: irreversible or reversible sample
anonymization. Informed consent places itself as a bal-
ance between the expression of the individual rights and
society’s interest. Given the importance of the informa-
tion process on tissue residual material biobanking to
the decision-making process about donation, we argue
that issues surrounding residual material collections for
biobanking should enter into public debate.
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